Study of the Safety and Efficacy of Intravenous Alpha-1 Antitrypsin in Type 1 Diabetes Mellitus
Status:
Completed
Trial end date:
2012-11-01
Target enrollment:
Participant gender:
Summary
Alpha-1 Antitrypsin (AAT), trade name (Glassia ®), is being explored in this phase I/II trial
as a potential disease modifying agent in Type 1 Diabetes Mellitus (T1DM) based on its
anti-inflammatory properties. AAT is an acute stress reactant protein that increases during
inflammation. In T1DM inflammation serves a major role in disease progression.